Suppr超能文献

组成性激活的ALK2和增加的SMAD1/5协同诱导进行性骨化性纤维发育不良中的骨形态发生蛋白信号传导。

Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.

作者信息

Fukuda Toru, Kohda Masakazu, Kanomata Kazuhiro, Nojima Junya, Nakamura Atsushi, Kamizono Jyunji, Noguchi Yasuo, Iwakiri Kiyofumi, Kondo Takeo, Kurose Junichi, Endo Ken-ichi, Awakura Takeshi, Fukushi Junichi, Nakashima Yasuharu, Chiyonobu Tomohiro, Kawara Akira, Nishida Yoshihiro, Wada Ikuo, Akita Masumi, Komori Tetsuo, Nakayama Konosuke, Nanba Akira, Maruki Yuichi, Yoda Tetsuya, Tomoda Hiroshi, Yu Paul B, Shore Eileen M, Kaplan Frederick S, Miyazono Kohei, Matsuoka Masaru, Ikebuchi Kenji, Ohtake Akira, Oda Hiromi, Jimi Eijiro, Owan Ichiro, Okazaki Yasushi, Katagiri Takenobu

机构信息

Division of Pathophysiology, Research Center for Genomic Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka-shi, Saitama 350-1241, Japan.

出版信息

J Biol Chem. 2009 Mar 13;284(11):7149-56. doi: 10.1074/jbc.M801681200. Epub 2008 Aug 6.

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder characterized by congenital malformation of the great toes and by progressive heterotopic bone formation in muscle tissue. Recently, a mutation involving a single amino acid substitution in a bone morphogenetic protein (BMP) type I receptor, ALK2, was identified in patients with FOP. We report here that the identical mutation, R206H, was observed in 19 Japanese patients with sporadic FOP. This mutant receptor, ALK2(R206H), activates BMP signaling without ligand binding. Moreover, expression of Smad1 and Smad5 was up-regulated in response to muscular injury. ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin. Taken together, these findings suggest that the heterotopic bone formation in FOP may be induced by a constitutively activated BMP receptor signaling through Smad1 or Smad5. Gene transfer of Smad7 or inhibition of type I receptors with dorsomorphin may represent strategies for blocking the activity induced by ALK2(R206H) in FOP.

摘要

进行性骨化性纤维发育不良(FOP)是一种罕见的常染色体显性疾病,其特征为大脚趾先天性畸形以及肌肉组织中进行性异位骨形成。最近,在FOP患者中发现了一种涉及骨形态发生蛋白(BMP)I型受体ALK2中单个氨基酸替代的突变。我们在此报告,在19例日本散发性FOP患者中观察到了相同的突变R206H。这种突变受体ALK2(R206H)在没有配体结合的情况下激活BMP信号传导。此外,响应肌肉损伤,Smad1和Smad5的表达上调。带有Smad1或Smad5的ALK2(R206H)诱导成骨细胞分化,而这种分化可被Smad7或多效唑抑制。综上所述,这些发现表明FOP中的异位骨形成可能是由通过Smad1或Smad5的组成型激活的BMP受体信号传导诱导的。Smad7的基因转移或用多效唑抑制I型受体可能代表了阻断ALK2(R206H)在FOP中诱导的活性的策略。

相似文献

3
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9. doi: 10.1016/j.bbrc.2008.10.093. Epub 2008 Oct 24.
8
Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).
Dev Biol. 2021 Feb;470:136-146. doi: 10.1016/j.ydbio.2020.11.004. Epub 2020 Nov 17.
9
Role of matrix metalloproteinase-10 in the BMP-2 inducing osteoblastic differentiation.
Endocr J. 2013;60(12):1309-19. doi: 10.1507/endocrj.ej13-0270. Epub 2013 Sep 28.

引用本文的文献

1
Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation.
Curr Drug Targets. 2025;26(5):350-366. doi: 10.2174/0113894501359782241216082049.
2
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity.
Nat Rev Rheumatol. 2025 Feb;21(2):77-87. doi: 10.1038/s41584-024-01189-3. Epub 2024 Dec 2.
4
Fibrodysplasia ossificans progressiva: Two case reports.
Radiol Case Rep. 2024 May 3;19(8):2973-2977. doi: 10.1016/j.radcr.2024.04.019. eCollection 2024 Aug.
5
Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva.
Biomedicines. 2024 Apr 2;12(4):779. doi: 10.3390/biomedicines12040779.
6
BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.
Circulation. 2024 Jul 9;150(2):132-150. doi: 10.1161/CIRCULATIONAHA.123.066430. Epub 2024 Apr 1.
7
The HIF-1α and mTOR Pathways Amplify Heterotopic Ossification.
Biomolecules. 2024 Jan 24;14(2):147. doi: 10.3390/biom14020147.
9
How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.
Biomolecules. 2024 Jan 12;14(1):101. doi: 10.3390/biom14010101.

本文引用的文献

1
Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP).
J Bone Miner Metab. 2008;26(6):521-30. doi: 10.1007/s00774-008-0879-8. Epub 2008 Nov 1.
2
Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
Circ Res. 2008 Apr 25;102(8):914-22. doi: 10.1161/CIRCRESAHA.107.165530. Epub 2008 Feb 28.
3
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
Nat Chem Biol. 2008 Jan;4(1):33-41. doi: 10.1038/nchembio.2007.54. Epub 2007 Nov 18.
4
Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors.
J Biol Chem. 2007 Jul 13;282(28):20603-11. doi: 10.1074/jbc.M702100200. Epub 2007 May 10.
5
The ACVR1 617G>A mutation is also recurrent in three Japanese patients with fibrodysplasia ossificans progressiva.
J Hum Genet. 2007;52(5):473-475. doi: 10.1007/s10038-007-0128-3. Epub 2007 Mar 10.
6
Hematopoietic stem-cell contribution to ectopic skeletogenesis.
J Bone Joint Surg Am. 2007 Feb;89(2):347-57. doi: 10.2106/JBJS.F.00472.
7
Dysregulation of the BMP-4 signaling pathway in fibrodysplasia ossificans progressiva.
Ann N Y Acad Sci. 2006 Apr;1068:54-65. doi: 10.1196/annals.1346.008.
9
Purification and identification of a BMP-like factor from bovine serum.
Biochem Biophys Res Commun. 2006 Jul 7;345(3):1224-31. doi: 10.1016/j.bbrc.2006.05.045. Epub 2006 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验